Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial

Jiménez‐Quevedo, Pilar; Hernando, Lorenzo; Gómez‐Hospital, Joan Antoni; Íñiguez, Andrés; Sanromán, A.L; Alfonso, Fernándo; Hernández‐Antolín, Rosana; Angiolillo, Dominick J.; Bañuelos, Camino; Escaned, Javier; Gonzalo, Nieves; Fernández, Cristina; Macaya, Carlos; Sabaté, Manel; Investigators, Diabetes

doi:10.4244/eijv9i3a54

Cited by 20 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This benefit was maintained up to five-year follow-up. 52 Subsequently, three other randomized trials also designed for diabetic patients (SCORPIUS, 53 DESSERT, 54 and DECODE 55 ) have corroborated the same positive results of SES in reducing neointimal proliferation (Table 3). A recent meta-analysis of all available data in diabetics treated with PCI demonstrated the benefit of SES in terms of restenosis and target lesion revascularization.…”

Section: Clinical Studiesmentioning

confidence: 74%

Safety and Long-Term Efficacy of Sirolimus-Eluting Stents

Regueiro¹,

Sabat²

2014

Clinical Medicine Reviews in Vascular Health

View full text Add to dashboard Cite

show abstract

Section: Clinical Studiesmentioning

confidence: 74%

Safety and Long-Term Efficacy of Sirolimus-Eluting Stents

Regueiro¹,

Sabat²

2014

Clinical Medicine Reviews in Vascular Health

View full text Add to dashboard Cite

show abstract

“…The study considered a sub-randomisation, according to the type of anti-diabetic treatment and the SES benefit was independent from diabetic status. This benefit was maintained up to 5-year follow-up [64]. Subsequently, 3 other randomised trials also designed for diabetic patients (SCORPIUS [65,66], DESSERT [67] and DECODE [68]) have corroborated the same positive results of SES in reducing neointimal proliferation to mid and long-term.…”

Section: Percutaneous Revascularisation In Diabetic Patientsmentioning

confidence: 74%

Percutaneous Coronary Intervention in Diabetic Patients

Paeres¹,

Hennessey²,

Sabaté³

et al. 2021

Interventional Treatment for Structural Heart Disease

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is responsible for 30% of deaths worldwide and is the leading cause of premature mortality in patients with diabetes mellitus (DM). One of the main contributors to the increased atherothrombotic risk in DM patients relates to their pro- inflammatory and prothrombotic status that involves abnormalities in endothelial and vascular smooth muscle cells, in platelet function and the coagulation cascade. The characteristics of CAD in diabetic patients is distinctive and infers an increased risk. Likewise, CAD in diabetics is characterised by being diffuse, affecting the left main stem more frequently, involving multiple vessels, and also affecting the distal coronary tree. Percutaneous coronary intervention in diabetics has been shown to have less favourable long-term clinical outcomes, compared to non-diabetics. With the advent of improved stent designs and antiplatelet drugs; the percutaneous coronary intervention (PCI) results have improved in the diabetic population. However, one of the main determinants of poorer outcomes in DM is the progression of atherosclerosis, which is more pronounced in diabetics and remains the primary cause of cardiac events at one year follow up after percutaneous revascularisation. Whilst new generation of drug-eluting stents has narrowed the gap between surgery and PCI in diabetic patients, coronary artery bypass grafting (CABG) remains the gold standard in diabetics with diffuse multivessel coronary artery disease.

show abstract

“…At 270 days, TLR was reduced in diabetic patients from 22.3% with BMS to 6.9% with SES (p < 0.001) and MACE were reduced from 25 to 9.2%, respectively (p < 0.001) (FIGURES 1 & 2) [8]. Reduction in 9-month TLR and cumulative MACE were maintained at 5 year with SES compared with BMS (7.3 vs 31.3% and 15.6 vs 45.5%, respectively) in the subsequent DIABETES trial (n = 160) [9,10].…”

Section: Bare Metal Stents Eramentioning

confidence: 82%

Evolution of coronary stents in patients with diabetes: are clinical outcomes still improving?

Kassimis

Maria

Patel

et al. 2014

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Diabetic patients are prone to diffuse and accelerated atherosclerosis, which increases the likelihood of requiring myocardial revascularization. Diabetes mellitus is a strong risk factor for restenosis following coronary stenting, with greater need for repeat revascularization and inferior clinical outcomes. Despite the recent advances in drug-eluting stent technology, diabetic patients are still at higher risk of adverse clinical events after coronary angioplasty. The focus of this review is to describe the evolution of the percutaneous management of diabetic patients with coronary artery disease and to define if any real progress has been made in terms of safety and efficacy with the use of the second generation drug-eluting stents in this high-risk population.

show abstract

Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial

Abstract: Five-year follow-up of the DIABETES trial suggests the effect of SES in reducing TLR is similar in both IDDM and NIDDM. No major safety concerns in terms of ST, MI or mortality were observed.

Cited by 20 publications

References 22 publications

Safety and Long-Term Efficacy of Sirolimus-Eluting Stents

Safety and Long-Term Efficacy of Sirolimus-Eluting Stents

Percutaneous Coronary Intervention in Diabetic Patients

Evolution of coronary stents in patients with diabetes: are clinical outcomes still improving?

Contact Info

Product

Resources

About